Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) W. J. HeinzD. BuchheidtG. Maschmeyer Review Article Open access 30 August 2017 Pages: 1775 - 1792
Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia Yinjun LouYafang MaJie Jin Original Article 19 August 2017 Pages: 1793 - 1800
Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy Sang-Bo OhSung-Woo Parkon behalf of the Hematology Association of South-East Korea (HASEK) study group Original Article 21 August 2017 Pages: 1801 - 1809
A comparison of therapeutic dosages of decitabine in treating myelodysplastic syndrome: a meta-analysis Bo YangRuili YuXuechun Lu Original Article 25 August 2017 Pages: 1811 - 1823
Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS) Myrna CandelariaSebastian BurgosAlfonso Dueñas-Gonzalez Original Article 23 August 2017 Pages: 1825 - 1832
The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment Natalia LorenzanaLaura Francisca AvilaTeresa Bernal Original Article 13 August 2017 Pages: 1833 - 1840
A cross-sectional study on late taste disorders in survivors of allogeneic hematopoietic cell transplantation Tomoko SatoTakaaki KonumaArinobu Tojo Original Article 16 August 2017 Pages: 1841 - 1847
Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation Jiaqian QiJie WangYue Han Original Article 11 August 2017 Pages: 1849 - 1855
Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study Martin KropffMartin VogelWolfgang E. Berdel Original Article 14 September 2017 Pages: 1857 - 1866
Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations Xin-xin CaoJian LiDao-bin Zhou Original Article 12 August 2017 Pages: 1867 - 1871
Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores Hyewon LeeYu Ri KimJin Seok Kim Original Article 22 August 2017 Pages: 1873 - 1881
PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma Young Wha KohJae-Ho HanJooryung Huh Original Article 25 August 2017 Pages: 1883 - 1890
Uterine intravascular lymphoma as a cause of fever of unknown origin Jérôme HadjadjHubert NiellyDavid Boutboul Original Article 29 August 2017 Pages: 1891 - 1896
Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly A. PartanenJ. ValtolaE. Jantunen Original Article 07 September 2017 Pages: 1897 - 1906
Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia Elias H. AttaCarlos B. L. LimaPhillip Scheinberg Original Article 16 August 2017 Pages: 1907 - 1914
Life-threatening bleeding episodes in primary immune thrombocytopenia: a single-center retrospective study of 169 inpatients Hiroyuki TsudaTakahiro TsujiHiroshi Yamasaki Original Article 14 August 2017 Pages: 1915 - 1920
Widening the spectrum of deletions and molecular mechanisms underlying alpha-thalassemia José FerrãoMarisa SilvaPaula Faustino Original Article 08 September 2017 Pages: 1921 - 1929
Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT) D. MairaE. CassinerioM. D. Cappellini Original Article 05 September 2017 Pages: 1931 - 1936
Evaluation of the Greek TranQol: a novel questionnaire for measuring quality of life in transfusion-dependent thalassemia patients Philippos KlonizakisRobert KlaassenEfthymia Vlachaki Original Article 07 September 2017 Pages: 1937 - 1944
Effects of realgar (As4S4) on degradation of PML-RARA harboring acquired arsenic-resistance mutations Mingshan NiuYangling ShenKailin Xu Letter to the Editor 18 August 2017 Pages: 1945 - 1948
Somatic mutations of calreticulin in patients with myelodysplastic/myeloproliferative neoplasms-unclassifiable Xueya ZhangJingxin Pan Letter to the Editor 17 August 2017 Pages: 1949 - 1951
Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia Alessandra IurloCristina BucelliAgostino Cortelezzi Letter to the Editor 19 August 2017 Pages: 1953 - 1954
A novel heterozygous ALAS2 mutation in a female with macrocytic sideroblastic anemia resembling myelodysplastic syndrome with ring sideroblasts: a case report and literature review Tohru FujiwaraNoriko FukuharaHideo Harigae Letter to the Editor 24 August 2017 Pages: 1955 - 1957
Durable remission is achievable with localized treatment and reduction of immunosuppression in limited stage EBV-related plasmablastic lymphoma C. PhippsK. W. YeohN. F. Grigoropoulos Letter to the Editor 22 August 2017 Pages: 1959 - 1960
Relative abundance of β-thalassemia-related mutations in southern China correlates with geographical coordinates Yingying ZhaoShenming GuanLe Cheng Letter to the Editor 05 September 2017 Pages: 1961 - 1963